Looking back on life sciences tools & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including PacBio (NASDAQ: PACB) and its peers.

The life sciences tools and services sector supports biotech and pharmaceutical R&D and commercialization by providing lab equipment, data analytics, and clinical trial services. These companies benefit from recurring revenue and high margins on specialized products. Looking ahead, the sector is supported by tailwinds like advancements in genomics, personalized medicine, and the use of AI in drug discovery. However, the persistent challenge is dependence on the R&D budgets of large pharmaceutical companies and the volatility of smaller biotech firms. Future headwinds include uncertain research funding and pricing pressures from cost-conscious customers.

The 21 life sciences tools & services stocks we track reported a satisfactory Q1. As a group, revenues beat analysts’ consensus estimates by 1.2% while next quarter’s revenue guidance was in line.

Luckily, life sciences tools & services stocks have performed well with share prices up 10.2% on average since the latest earnings results.

PacBio (NASDAQ: PACB)

Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ: PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness.

PacBio reported revenues of $37.18 million, flat year on year. This print fell short of analysts’ expectations by 7.1%. Overall, it was a softer quarter for the company with a significant miss of analysts’ revenue estimates.

“We continue to see increasing clinical adoption of HiFi which contributed to another record quarter for consumable revenue. However, instrument revenue, particularly Vega, was lower than we had expected," said Christian Henry, President and Chief Executive Officer.

PacBio delivered the weakest performance against analyst estimates of the whole group. Unsurprisingly, the stock is down 6.4% since reporting and currently trades at $1.55.

Read our full report on PacBio here, it’s free.

Best Q1: West Pharmaceutical Services (NYSE: WST)

Founded in 1923 and serving as a critical link in the pharmaceutical supply chain, West Pharmaceutical Services (NYSE: WST) manufactures specialized packaging, containment systems, and delivery devices for injectable drugs and healthcare products.

West Pharmaceutical Services reported revenues of $844.9 million, up 21% year on year, outperforming analysts’ expectations by 8.4%. The business had a stunning quarter with a beat of analysts’ EPS and revenue estimates.

West Pharmaceutical Services achieved the biggest analyst estimate beat among its peers. The market seems happy with the results as the stock is up 18% since reporting. It currently trades at $323.85.

Is now the time to buy West Pharmaceutical Services? Access our full analysis of the earnings results here, it’s free.

Weakest Q1: Azenta (NASDAQ: AZTA)

Serving as the guardian of some of medicine's most valuable materials, Azenta (NASDAQ: AZTA) provides biological sample management, storage, and genomic services that help pharmaceutical and biotechnology companies preserve and analyze critical research materials.

Azenta reported revenues of $144.8 million, up 1% year on year, falling short of analysts’ expectations by 2.5%. It was a disappointing quarter as it posted a significant miss of analysts’ revenue and EPS estimates.

As expected, the stock is down 5.8% since the results and currently trades at $23.19.

Read our full analysis of Azenta’s results here.

Bruker (NASDAQ: BRKR)

With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ: BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels.

Bruker reported revenues of $823.4 million, up 2.7% year on year. This number beat analysts’ expectations by 3.4%. Overall, it was a very strong quarter as it also put up a beat of analysts’ EPS and revenue estimates.

The stock is up 56% since reporting and currently trades at $59.30.

Read our full, actionable report on Bruker here, it’s free.

Illumina (NASDAQ: ILMN)

Pioneering the ability to read the human genome at unprecedented speed and affordability, Illumina (NASDAQ: ILMN) develops and sells advanced DNA sequencing and microarray technologies that allow researchers and clinicians to analyze genetic variations and functions.

Illumina reported revenues of $1.09 billion, up 4.8% year on year. This result topped analysts’ expectations by 1.8%. It was a strong quarter as it also produced a solid beat of analysts’ full-year EPS guidance estimates.

The stock is up 29.1% since reporting and currently trades at $163.68.

Read our full, actionable report on Illumina here, it’s free.

Market Update

Late in 2025 into early 2026, there was hand-wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure?

These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability.

Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.